T1	p 72 123	zoster vaccine in healthy adults ?60 years of age .
T2	p 161 208	herpes zoster ( HZ ) and postherpetic neuralgia
T3	p 218 226	with age
T4	p 507 538	with 210 subjects ?60 years old
T5	p 1674 1696	adults ?60 years old .
T6	i 604 606	ZV
T7	i 622 645	6 weeks , vs. placebo .
T8	i 675 812	using VZV interferon-gamma ( IFN-? ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody
T9	i 855 858	AEs
T10	i 893 904	Vaccination
T11	i 912 916	Card
T12	i 1304 1311	placebo
T13	i 1500 1507	placebo
T14	o 6 48	Safety , tolerability , and immunogenicity
T15	o 561 567	safety
T16	o 646 660	Immunogenicity
T17	o 681 860	VZV interferon-gamma ( IFN-? ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody ( gpELISA ) assay . Adverse experiences ( AEs )
T18	o 880 918	standardized Vaccination Report Card .
T19	o 927 1095	No serious vaccine-related AEs occurred . VZV IFN-? ELISPOT geometric mean count ( GMC ) of spot-forming cells per 10 ( 6 ) peripheral blood mononuclear cells increased
T20	o 1352 1377	The peak ELISPOT response
T21	o 1421 1459	gpELISA geometric mean titers ( GMTs )
T22	o 1563 1599	the IFN-? ELISPOT and gpELISA assays
T23	o 1640 1670	well-tolerated and immunogenic
T24	o 1756 1777	VZV-specific immunity
T25	o 1801 1809	postdose